ERBB2 and neoplasm: We aimed to investigate the combined role of the tumour immune microenvironment and HER2-low status in predicting chemosensitivity and intrinsic resistance in this specific population.<h4>Methods</h4>We retrospectively analysed data from 767 premenopausal patients with TNBC across two Chinese medical centres.